Proton therapy eliminates 70% of liver cancer tumors – A Korean study

Share This Post

Researchers at Samsung Medical Center in South Korea published a study showing that proton therapy is an effective and safe method of treating liver cancer. Proton therapy is a high-end radiotherapy method that uses proton rays instead of the photon rays (X-ray and γ-ray) used in ordinary radiotherapy to destroy cancer cell DNA, interfere with its replication and reproduction, and cause cancer cell death.

The team of Park Hee-chul and Yu Jeong-il, professors of the Department of Radiation Oncology at Samsung Medical Center, studied 101 liver cancer patients who had undergone proton therapy for one year from January 2016. The results of the study showed that almost all patients who used proton therapy as a substitute for local cautery therapy (such as surgery or high-frequency hyperthermia) were significantly improved.

78 patients were followed up for 3 months after proton therapy. About 70% (54 patients) tumors completely disappeared and about 18% (14 patients) tumors shrank significantly. After treatment, in the Child-Pugh score, nearly 90% of patients maintained Grade A status in the Child-Pugh score for 3 months.

The researchers said that patient safety is considered to be the biggest advantage of proton therapy and has been confirmed by research. Samsung Medical Center pointed out that proton therapy can reduce the adverse effects of existing radiation therapy, and only a lower dose of radiation can achieve better treatment results. “Although we are in the initial stage of developing proton therapy, data published in developed countries: In the long run, proton therapy will bring positive results to patients,” Professor Park said.

 

“Through further research, we will focus on improving the quality of life of patients, through further research to improve the treatment effect and improve the treatment side effects,” Park added. The results were published in the latest issue of the Korean Society of Radiation Oncology (KOSRO).

Affordable cancer treatment in Singapore

You may like to read: Proton therapy in Sinagpore

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy